CA
NZ
UK
AU
IND
US
• On June 24 2026 KORU Medical and Command Medical Products executed Amendment No. 1 to their 2024 manufacturing agreement.
• Joseph Manhede appointed as Principal Accounting Officer.
• Nuvectis Pharma (NASDAQ: NVCT) priced 5,000,000 shares at $20.00 per share in a firm commitment offering.
• Oramed Pharmaceuticals (NASDAQ: ORMP) approved amended bylaws simplifying stockholder consent procedures under Delaware law.
• Perrigo Company plc (NYSE: PRGO) expands its board from eight to ten members with two new independent directors.
• BioAffinity Technologies reported a significant increase in CyPath Lung test sales, indicating rising demand.
• Celularity (NASDAQ: CELU) received a $1 million loan from an insider trust linked to the Barach family.
• Catalyst Pharmaceuticals issued a press release on June 30 2026 announcing topline data from a two‑part Phase 1 study of AGAMREE (vamorolone).
• Gossamer Bio Inc. (NASDAQ: GOSS) established an initial conversion rate of 5,347.5936 shares per $1,000 principal for its 7.50% convertible notes due 2030.
• IBio’s IBIO-610 reduced active Activin E levels by 98% at week 4 in obese non-human primates after a single dose.
Please wait processing your request...